Purpose. We sought to explore the current status of antifungal stewardship (AFS) initiatives across National Health Service (NHS) Trusts within England, the challenges and barriers, as well as ways to improve current AFS programmes.
INTRODUCTION
Antimicrobial stewardship (AMS) initiatives have until recently largely focussed on antibacterial agents. However, a number of recent studies have highlighted the importance of antifungal stewardship (AFS), outlining significant patient benefits, as well as cost-savings [1] [2] [3] [4] [5] . Issues addressed in AFS include selection of the most appropriate agent in terms of intrinsic antifungal activity [6] , whether additional diagnostic or biomarker tests are required, dose (especially with major organ dysfunction), drug interactions (which are a major issue with the azole antifungals) [7] , underlying therapy plan (increased or reduced immunosuppression, renal support, etc.), addressing current or future adverse events advising on therapeutic drug monitoring (TDM) [8] , potential for antifungal resistance and oral switch possibilities. Resistance to antifungal agents is an emerging concern, whether due to intrinsically resistant fungi (e.g. Candida krusei, Candida auris [9] , Mucorales and Fusarium spp.) or due to isolates with acquired resistance (e.g. Candida glabrata and Aspergillus fumigatus). Dual fungal infection is an increasing problem [10] , which has the potential to increase antifungal usage. Better antifungal choices improve outcomes and reduce cost [5, 6] . Better availability and usage of non-culture-based fungal diagnostics should also reduce unnecessary anti-bacterial use [11] . We sought to explore the current status of AFS initiatives across National Health Service (NHS) acute Trusts within England.
METHODS
A web-based survey containing 50 closed questions was developed and deployed by Public Health England's select survey programme as previously described [12] , in order to explore the status of AFS in England. There was also the opportunity to provide comments (i.e. free text). The final draft was piloted amongst the group for face validity and disseminated to all 155 NHS acute hospital Trusts across England via the following networks: the Lead Public Health Microbiologists (Public Health England) network and British Infection Association (targeting principally microbiology and infectious disease consultants), the UK Clinical Pharmacy Association, (targeting hospital chief pharmacists), the Pharmacy Infection Network and the East of England antimicrobial pharmacist group (targeting infection pharmacists). The survey was open for 6 weeks and reminders were issued at 3 weeks and again at 5 weeks. All NHS hospitals in England were included. NHS hospitals in Wales, Northern Ireland and Scotland, and all UK hospitals were excluded. The responses were first de-duplicated to remove multiple responses from individuals but multiple responses from the same Trusts were retained if they were from different healthcare professionals (i.e. pharmacists, microbiologists, etc.). Responses from non-English Trusts were also excluded from the analysis. Results were analysed using Microsoft Excel.
RESULTS
In total, 47 acute Trusts in England responded to the questionnaire, representing 30 % of all acute Trusts. The majority (53 %; 25) were district general hospitals Trusts (small, medium and large acute Trusts), followed by teaching (36 %; 17) and specialist Trusts (11 %; 5) ( Table 1) . Most respondents were microbiologists (37; 69 %), followed by antimicrobial pharmacists and infectious disease physicians. A wide range of specialities were covered by participating hospitals.
Only one English NHS acute Trust reported that it had no AMS programme in place (a specialist hospital). This contrasts with only five Trusts (11 %) reporting to have a dedicated AFS programme. Four of these were in teaching Trusts and one was in a specialist Trust. However, 20 hospitals (43 %) included AFS as part of their AMS programme and 12 (26 %) monitored antifungal use. Nine Trusts (19 %) had no AFS programme. Most (76 %) Trusts have guidelines for the treatment and/or prophylaxis of invasive fungal infections.
Perceived potential benefits of AFS included improvements in safety (23), outcome (19), costs (24), reduced side-effects (20) and obtaining surveillance data (18).
Most acute Trusts had access to a number of available laboratory tests (e.g. galactomannan, cryptococcal antigen, b-D-glucan; Table 1 ). Interestingly, availability of laboratory testing was not related to the type of hospital Trust (e.g. district general hospital Trust, teaching Trust; data not shown). Of concern is the slow turnaround time reported in the questionnaire; most results were unavailable for at least 48 h.
Most AFS activities were performed by a microbiologist, followed by an antimicrobial pharmacist, infectious disease physician or other pharmacist. A variety of models were suggested. Seven Trusts reported having an AFS/management team, while five reported performing dedicated AFS ward rounds. Twelve Trusts said they offered advice on patients with invasive fungal infections. Several Trusts said they saw fungaemic patients on their general daily ward rounds. A number of respondents identified that they perform ward rounds on haematology wards and intensive care units within their hospitals. Some Trusts with no dedicated AFS programme nevertheless included patients on antifungal agents as part of their AMS work. One respondent suggested they reviewed patients on a list of 'restricted drugs' as part of their AMS round, which included high-cost antifungal agents. Most suggested they performed their AFS programme weekly, but some respondents did it more frequently. Other Trusts did it as required on an ad hoc basis.
One respondent suggested they approached AFS using an analogy from infection prevention: 'there is a role for the infection prevention team but daily infection prevention activities are in everybody's job description. Our AFS team does not do specific AFS ward rounds -we have empowered the specialists in various clinical teams (champions) to look after this when they do their normal ward rounds. We support them and help them with audits but optimal antifungal prescribing is their responsibility'. This approach occurred in a hospital with a significant number of patients at risk of fungal infections.
There were a variety of different reasons for commencing an AFS programme including: financial concerns (13; 52 %), clinical need (12; 48 %), attempts to improve patient management (40 %) and interested individuals. Interestingly, only two respondents suggested concerns about antifungal resistance as a reason for starting their programme. A variety of resources were used for commencing AFS. The most frequent resource cited was discussions (with colleagues or experts), teaching events/meetings and literature searches. One specialist Trust recruited two medical mycologists specifically to set up an AFS programme, whilst another AFS programme resulted from an audit of antifungal prescribing. Reduced side-effects 20 43
Obtain surveillance data to devise antifungal treatment guidelines 18 39 Request from clinicians 0 0 Patients were identified by a variety of different mechanisms. Pharmacy records were used to detect patients receiving antifungal agents (18), via microbiology results (13) and queries from clinicians (15) . Six respondents performed specialty-specific ward rounds.
Many centres have an antimicrobial pharmacist (19; across all hospital types), a microbiologist or infectious disease physician, a database and access to TDM. A small majority of Trusts performed TDM (57 %).
Most respondents reported that as part of their AFS programme, they assessed clinical response (19), highlighted drug-drug interactions (15) , addressed side-effects (14) and ensured appropriate use of TDM/fungal biomarkers (17 each). Other comments included checking compliance to guidelines/evidence based use. Measures used to assess effectiveness included monitoring the likelihood of obtaining adequate therapeutic drug levels (17), costs of antifungal agents (13) , resistance profile (10) and mortality data (5) . Other Trusts obtained surveillance data as part of their AFS programme. Most respondents thought their advice was 'usually' followed, though some suggested it was 'sometimes' followed.
The majority (79 %) of respondents would ideally perform more AFS duties. One respondent reported they had been required to suspend their AMS service (and hence AFS service) due to staffing issues.
A number of reasons were suggested by the 21 respondents who did not perform AFS. These included lack of time, competing priorities, perceived lack of importance and lack of expertise. Three respondents suggested that funding by NHS England for high-cost antifungal drugs was a reason for not performing AFS (so any financial savings did not benefit the Trust). Other reasons for not performing AFS included 'lower numbers'/'antifungal use is relatively less' and lack of interest/ engagement from other specialties (e.g. haematology).
Availability of rapid diagnostics, clinical support (57 % each) and more resources (52 %) could help persuade some clinicians to start an AFS service, but teaching events (43 %) and E-learning programmes (29 %) were not considered to be beneficial.
DISCUSSION
The clinical and financial benefits of AFS are well described [1] [2] [3] [4] [5] . Most studies to date have suggested financial benefits as the principal reason for performing it. However, even small studies targeting the management of patients with candidaemia have shown improvements in mortality [13] . There are important differences between AMS and AFS ( Table 2) . Clinicians are less familiar with fungal infections in terms of diagnostics and therapy, some drugs can be toxic and the azole antifungal agents have multiple interactions. Some antifungals are expensive. Patients with fungal infections (or suspected fungal infection) also typically have multiple co-morbidities and/or are extremely unwell.
We provide data on an important and emerging area from a national survey. Most respondents recognised the potential benefits of an AFS programme. Not surprisingly, most acute NHS Trusts in England responded to say they had an AMS programme in place. We found that microbiologists and antimicrobial pharmacists are the clinicians most involved in AFS. However, only 76 % of acute Trusts had guidelines for the treatment and/or prophylaxis of fungal infections and only 57 % of Trusts performed TDM on some azoles, despite national guidelines suggesting its importance, especially for long-term voriconazole use, paediatrics and complex clinical situations, usually in critical care [8] .
A variety of methods for performing AFS are described, from dedicated ward rounds (at least weekly) to ad hoc arrangements as and when required. This varied according to institution. Some hospitals perform it as part of their AMS programme (suspended due to lack of resources in at least one hospital at the time of survey) whilst one specialist Trust had appointed two mycologists to help with AFS. Patients were typically identified by either laboratory results or pharmacy records in most cases. Most Trusts had access to a range of fungal biomarkers, although not necessarily in their own Trust. However, the turnaround times were typically prolonged (>48 h), which limits their clinical impact and utility for clinicians. This was highlighted in comments from several respondents. Fungal diagnostics is an area of difficulty for many clinicians and hugely important if antifungal agents are to be used appropriately. There is some evidence from this survey that some clinicians are unfamiliar and not confident with their interpretation. One laboratory expressed dissatisfaction in the funding of diagnostic tests (funded for certain patients but not others).
Most respondents thought their advice was 'usually' followed. However, the comments section suggests some areas (e.g. haematology/respiratory medicine) are less engaged or reluctant to follow advice from an AFS team of microbiologist and antimicrobial pharmacist. One Trust circumvented the issue by giving ownership back to the clinical team, who are ultimately responsible for the patient.
Most respondents who perform AFS would do more if they had the available resources. One Trust had reduced its AFS programme as a clinician had left and not been replaced. Standiford and colleagues reported the situation where costs fell when an AFS programme (as part of an AMS programme) was instituted and then rose when it was withdrawn [1] .
The funding mechanism in England is different from other countries within the UK. Most systemic antifungals, excluding fluconazole, itraconazole and flucytosine are classified as high-cost drugs, and are funded separately outside of the payment by results or tariff system. Hospitals are required to provide patient-level information to receive direct payment for the antifungals they use. A national quality, innovation, productivity and prevention incentive scheme has slightly reduced consumption on high-cost antifungals as defined daily doses, but the use of antifungals with expired or soon to expire patents (i.e. voriconazole and caspofungin) where cheaper costs will be seen has actually fallen. Most of the savings seen from the use of generic voriconazole has funded more expensive antifungals with years to run on their patents (data from www.rx-info.co.uk/products/ define/). Future NHS England incentive schemes are focusing on paying the lowest cost for 'off-patent' antifungals (www.england.nhs.uk/wp-content/uploads/2016/11/ge3-hospital-medicines-optimisation.pdf), but unless all highcost antifungals are removed from the tariff exclusion list, there will only be limited improvements in AFS.
Our study, in common with a number of questionnaire studies, has a number of limitations. The return rate was only 30 % which compares to other similar studies [14] but lower than a recent survey of AMS in the USA [15] . This study may have had a higher response rate (56 %) as it only targeted transplant centres and combined AMS and AFS. Nevertheless, we present data from a range of hospital Trusts of different types and involving different patient. Bias is inherent in any questionnaire; clinicians with an interest in AFS may have been more likely to respond than others. Another limitation is that we did not ask how successful the various programmes were [with actual metrics (e.g. decrease of antifungal consumption, improved outcomes/mortality rates or other outcome measures set for the AFS programme)] and what the respondents felt had been key for their success or lack of. We also did not ask why centres did not perform certain activities (such as TDM). Our study also does not describe how to develop an AFS programmes.
AFS has been shown to have significant benefits to patients. Our survey suggests that AFS is being performed in most English NHS hospital Trusts in a variety of different ways which in part reflects different patient populations. Most respondents indicated they would do more if they had the resources to do it, suggesting improvements can still be made.
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